title: Hepatitis: Treatment of chronic hepatitis C-how much interferon is enough?
abstract: A multicenter, randomized, controlled trial of 610 patients with chronic hepatitis c infected with hcv genotype 1 or 4 compared 48 weeks of standard of care therapy (PEG-IFN and ribavirin) with 12 weeks of induction therapy with high-dose PEG-IFN followed by 36 weeks of standard of care treatment. High-dose PEG-IFN induction therapy did not enhance early or sustained virologic response rates compared with standard of care therapy.
authors.affiliation: Medical University of Vienna, Internal Medicine III, Department of Gastroenterology and Hepatology, Waehringer Guertel 18-20, A1090 Vienna, Austria. peter.ferenci@meduniwien.ac.at
authors.forename: Peter
authors.initials: P
authors.lastname: Ferenci
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a